Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Mid America Heart Institute and University of Missouri-Kansas City, Missouri, USA. jhokeefe@cc-pc.com
Despite the fact that we possess highly effective tools for the primary and secondary prevention of myocardial infarction and other complications of atherosclerosis, coronary heart disease remains the most common cause of death in our society. Arterial inflammation and endothelial dysfunction play central roles in the pathogenesis of atherosclerosis and adverse cardiovascular (CV) events. Therapeutic lifestyle changes in conjunction with an aggressive multidrug regimen targeted toward the normalization of the major CV risk factors will neutralize the atherogenic milieu, reduce vascular inflammation, and markedly decrease the risk of adverse CV events and need for revascularization procedures. Specific CV risk factors and optimal therapies for primary and secondary prevention are discussed.
Images from this publication.See all images (7) Free text
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on